Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.
The Pharmaceutical Benefits Scheme (PBS) listing for dupilumab has been expanded to include the treatment of uncontrolled severe asthma in children from six years of age. The VOYAGE study evaluated the efficacy of dupilumab…
Read more
A new indication has been added to the product information of ipilimumab and nivolumab. Combination therapy with these medicines is now a first-line treatment option for unresectable or metastatic hepatocellular carcinoma in adults. This…
Read more
Vyalev® (foslevodopa + foscarbidopa) has been added to the Pharmaceutical Benefits Scheme (PBS) for the management of advanced Parkinson’s disease in patients with severe disabling motor fluctuations not adequately controlled by oral therapy. Many…
Read more
Ivosidenib has recently been added to the Pharmaceutical Benefits Scheme (PBS) for the treatment of locally advanced or metastatic cholangiocarcinoma. Eligibility requires the presence of an IDH1 R132 mutation and prior treatment with…
Read more
The Therapeutic Goods Administration (TGA) has issued a medicines safety update regarding the administration of respiratory syncytial virus (RSV) prevention products. These products include the two vaccines, Arexvy® and Abrysvo®, and the monoclonal antibody…
Read more
The Pharmaceutical Benefits Scheme (PBS) listing for Trikafta® (elexacaftor + tezacaftor + ivacaftor) has recently been expanded. Patients with cystic fibrosis are now eligible for subsidised therapy if they have at least one mutation…
Read more
